1. Home
  2. FATE vs RFAI Comparison

FATE vs RFAI Comparison

Compare FATE & RFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • RFAI
  • Stock Information
  • Founded
  • FATE 2007
  • RFAI 2024
  • Country
  • FATE United States
  • RFAI Singapore
  • Employees
  • FATE N/A
  • RFAI N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • RFAI
  • Sector
  • FATE Health Care
  • RFAI
  • Exchange
  • FATE Nasdaq
  • RFAI NYSE
  • Market Cap
  • FATE 108.2M
  • RFAI 154.8M
  • IPO Year
  • FATE 2013
  • RFAI 2024
  • Fundamental
  • Price
  • FATE $0.94
  • RFAI $10.36
  • Analyst Decision
  • FATE Hold
  • RFAI
  • Analyst Count
  • FATE 9
  • RFAI 0
  • Target Price
  • FATE $5.50
  • RFAI N/A
  • AVG Volume (30 Days)
  • FATE 3.4M
  • RFAI 13.1K
  • Earning Date
  • FATE 03-05-2025
  • RFAI 01-01-0001
  • Dividend Yield
  • FATE N/A
  • RFAI N/A
  • EPS Growth
  • FATE N/A
  • RFAI N/A
  • EPS
  • FATE N/A
  • RFAI N/A
  • Revenue
  • FATE $13,631,000.00
  • RFAI N/A
  • Revenue This Year
  • FATE N/A
  • RFAI N/A
  • Revenue Next Year
  • FATE N/A
  • RFAI N/A
  • P/E Ratio
  • FATE N/A
  • RFAI N/A
  • Revenue Growth
  • FATE N/A
  • RFAI N/A
  • 52 Week Low
  • FATE $0.87
  • RFAI $10.00
  • 52 Week High
  • FATE $7.70
  • RFAI $10.40
  • Technical
  • Relative Strength Index (RSI)
  • FATE 37.74
  • RFAI N/A
  • Support Level
  • FATE $0.87
  • RFAI N/A
  • Resistance Level
  • FATE $1.03
  • RFAI N/A
  • Average True Range (ATR)
  • FATE 0.12
  • RFAI 0.00
  • MACD
  • FATE -0.01
  • RFAI 0.00
  • Stochastic Oscillator
  • FATE 13.12
  • RFAI 0.00

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About RFAI RF ACQUISITION CORP II

RF Acquisition Corp II is a blank check company.

Share on Social Networks: